• Indian Indices
  • Global Indices
  • Commodities
  • Currency
Sensex
  • Sensex
  • Nifty
{{x.close_price| number:2}} {{x.netchg| number:2}} ({{x.perchg | number:2}}%)
Open - {{x.open | number:2}}
Prev Close - {{x.prevclose|number:2}}
Today's High - {{x.high|number:2}}
Today's Low - {{x.low|number:2}}
Advances/Declines (30 Companies)
  • 1D
  • 1W
  • 1M
  • 1Yr
  • 5Yr
{{x.upd_time}}
FTSE 100
  • FTSE 100
  • DJIA
  • NIKKEI 225
  • HANG SENG
{{x.Date}}
{{x.close| number:2}} {{x.Chg | number:2}} ({{x.PChg | number:2}}%)
Open - {{x.close | number:2}}
Prev Close - {{x.PrevClose|number:2}}
Gold
  • Gold
  • Silver
  • Crude Oil
  • Copper
{{x.Trd_Date}} ( {{x.Time}} )
{{x.ClosePrice| number:2}} {{x.change| number:2}} ({{x.perchange | number:2}}%)
Exchange - MCX
Open - {{x.Open|number:2}}
Exp Date - {{x.Exp_Date}}
Today's High - {{x.High|number:2}}
Prev. Close - {{x.PrevClose|number:2}}
Today's Low - {{x.Low|number:2}}
USDINR
  • USDINR
  • GBPINR
  • EURINR
  • JPYINR
{{x.Lasttrdtime}} ( {{x.Time}} )
{{x.ltp| number:2}} {{x.PriceDiff| number:2}} ({{x.PerChange | number:2}}%)
Exchange - NSE
Open - {{x.Open|number:2}}
Exp Date - {{x.Expirydate}}
Today's High - {{x.High|number:2}}
Prev. Close - {{x.PrevPrice|number:2}}
Today's Low - {{x.Low|number:2}}
As On 06-Dec-2019 EOD, Market Closed
SENSEX
40,445.15
-334.44 (-0.82%)
NIFTY
11,921.50
-96.90 (-0.81%)
    No Companies Visited

Back to news list
  • Suven Life tumbles after SUVN-502 misses target in phase-2 trial

    Suven Life Sciences slumped 14.85% to Rs 268.05 after the company said that its key molecule SUVN-502 (Masupirdine), meant for treatment of Alzheimer, did not meet the pre-specified primary endpoint.

    As part of the study, Suven Life tested the drug as a unique triple combination with Donepezil and Memantine on 564 Alzheimer's Disease (AD) patients in the US for at least one year. The trial compared the efficacy and safety of two doses of Masupirdine (50 mg and 100 mg per day) to placebo in moderate AD patients.

    Triple therapy of Masupirdine (SUVN-502) with Donepezil and Memantine proof of concept phase 2 study missed its pre-specified primary endpoint.

    "We are very disappointed with the outcome of this trial but the findings present an important step forward in further exploration of the potential therapeutic effects of Masupirdine (SUVN-502) in Alzheimer's Disease (AD) and Behavioral & Psychological Symptoms in Dementia (BPSD). We will work with regulators and potential partnering companies in the design and conduct of future studies for further exploration of the potential of Masupirdine (SUVN-502)," said Venkat Jasti, CEO of Suven.

    The announcement was made on Saturday, 30 November 2019.

    Meanwhile, the S&P BSE Sensex was up 1 point or flat at 40,794.34.

    In the past one month, shares of Suven Life Sciences fell 4.64% to its current market price of Rs 268.05, underperforming the Nifty Pharma index's 2.14% rise in the same period.

    On the technical front, the stock's RSI (relative strength index) stood at 37.148. The RSI oscillates between zero and 100. Traditionally the RSI is considered overbought when above 70 and oversold when below 30.

    The stock was currently trading below its 50-day moving average (DMA) placed at Rs 285.97, but above its 200 DMA placed at Rs 262.43.

    Suven Life Sciences' consolidated net profit surged 1,535.90% to Rs 63.31 crore on 206.4% surge in net sales to Rs 274.31 crore in Q2 September 2019 over Q2 September 2018.

    Suven Life Sciences is engaged in the business of manufacture and sale of bulk drugs and intermediaries.

    Back to news list
Previous Stories :
More
Hot Pursuit News

Quick Links

Formed in 1986, Capital Market Publishers India Pvt Ltd pioneered corporate databases and stock market magazine in India. Today Capitaline corporate database cover more than 35,000 listed and unlisted Indian companies. Latest technologies and standards are constantly being adopted to keep the database user-friendly, comprehensive and up-to-date.

Over the years the scope of the databases has enlarged to cover economy, sectors, mutual funds, commodities and news. Many innovative online and offline applications of these databases have been developed to meet various common as well as customized requirements.

While all the leading institutional investors use Capitaline databases, Capital Market magazine gives access to the databases to individual investors through Corporate Scoreboard. Besides stock market and company-related articles, the magazine’s independent and insightful coverage includes mutual funds, taxation, commodities and personal finance.

The power of the database is harnessed by our fired-up reporters to generate interesting ideas. The reader-friendly presentation of the idea, supplemented by relevant data and information, can be accessed online through Capita Telefolio and Telefolio Gold. These ideas are used by individual investors as well as institutional investors to do further research and stay ahead.

Capital Market Publishers India Pvt. Ltd.

401, Swastik Chambers, Sion Trombay Road, Chembur, Mumbai - 400 071.
91-22-25229720
91-22-25230011
Kindly note www.capitalmarket.com does not send any mobile SMS, whatsapp or twitter messages
giving any kind of stock recommendations.
For Capital Market Magazine Print Edition queries mail to : subscription@capitalmarket.com
For Capital Market Online Products related queries mail to : financeshop@capitalmarket.com
For any other Capital Market Website related Queries mail to : info@capitalmarket.com
To advertise on Capital Market Websites & Capital Market Fortnightly magazine mail to : advt@capitalmarket.com
Flash News 07-Dec-2019
  •  ( 09:05) Bank of India's board approves raising up to Rs 10,000 crore  
  •  ( 08:25) OPEC nations and Russia agree to cut oil output  
  •  ( 08:19) NEFT to be available 24x7 from December 16: RBI  
  •  ( 08:16) U.S. stocks closed sharply higher Friday after November jobs report  
Show News
06 December 2019 00:00
1717.35
(0.15 %)
717.55
(-1.64 %)
3205.85
(-1.19 %)
3950.45
(-0.93 %)
444.75
(-0.55 %)
2264.00
(-2.64 %)
560.20
(-0.10 %)
1246.20
(0.06 %)
2362.40
(-1.43 %)
2025.50
(-0.53 %)
524.75
(-0.60 %)
1463.75
(-3.05 %)
715.15
(0.07 %)
243.30
(-1.46 %)
1674.30
(1.48 %)
1290.30
(-0.87 %)
510.30
(-2.73 %)
6881.35
(-1.77 %)
112.55
(-1.32 %)
126.60
(-1.71 %)
186.55
(-0.32 %)
1554.95
(0.30 %)
319.80
(-4.89 %)
428.50
(-1.86 %)
161.50
(-2.77 %)
67.90
(-2.02 %)
402.95
(0.83 %)
2122.95
(0.07 %)
758.00
(-0.88 %)
141.95
(-0.35 %)
56.00
(-9.82 %)
Sensex 5min and Nifty 15min delayed as on .
Show Ticker
Rotate your device

Rotate your device

For the best experience please go back to portrait mode.